Patents by Inventor Walter A. Szarek
Walter A. Szarek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140155445Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.Type: ApplicationFiled: September 18, 2013Publication date: June 5, 2014Applicants: QUEEN'S UNIVERSITY AT KINGSTON, Osta Biotechnologies Inc., The Sir Mortimer B. Davis - Jewish General HospitalInventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
Patent number: 8632914Abstract: The present disclosure relates to certain new and known triazolium and/or imidazolium salts and to their therapeutic use, for example in methods of treating or preventing an infection by a Plasmodium or Babesia parasite in a subject in need thereof. The triazolium and imidazolium salts are compounds of the Formula (I) or (II): wherein R1-R4, R1?-R3?, R8-R11, X, X?, X?, Y, Y? and Y? are as defined in the disclosure.Type: GrantFiled: September 4, 2009Date of Patent: January 21, 2014Assignee: University Health NetworkInventors: Ian E. Crandall, Walter A. Szarek, Jason Z. Vlahakis
-
Patent number: 8513294Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumor tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.Type: GrantFiled: January 13, 2011Date of Patent: August 20, 2013Assignees: Osta Biotechnologies, Queens University at Kingston, The Sir Mortimer B. Davis-Jewish General HospitalInventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
Publication number: 20120020915Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.Type: ApplicationFiled: January 13, 2011Publication date: January 26, 2012Applicants: QUEENS UNIVERSITY AT KINGSTON, THE SIR MORTIMER B. DAVIS JEWISH GENERAL HOSPITAL, OSTA BIOTECHNOLOGIES, INC.Inventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
Publication number: 20110319459Abstract: Disclosed are compounds of the general formula (I): T?C?nD??(I), compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.Type: ApplicationFiled: April 14, 2011Publication date: December 29, 2011Applicants: OSTA BIOTECHNOLOGIES, The Sir Mortimer B. Davis - Jewish General Hospita, QUEENS UNIVERSITY AT KINGSTONInventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
Publication number: 20110281951Abstract: Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C?O), thiocarbonyl (C?S), sulfonyl (SO2), or sulfoxide (S?O) group. “k” and “m” are 0 or 1, provided when k is 1, R1 is not a hydrogen atom, and when m is 1, R2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. “p” and “s” are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound.Type: ApplicationFiled: April 14, 2011Publication date: November 17, 2011Inventors: Walter Szarek, Donald Weaver, Xianqi Kong, Heather Gordon
-
Publication number: 20110257235Abstract: The present disclosure relates to certain new and known triazolium and/or imidazolium salts and to their therapeutic use, for example in methods of treating or preventing an infection by a Plasmodium or Babesia parasite in a subject in need thereof. The triazolium and imidazolium salts are compounds of the Formula (I) or (II): wherein R1-R4, R1?-R3?, R8-R11, X, X?, X?, Y, Y? and Y? are as defined in the disclosure.Type: ApplicationFiled: September 4, 2009Publication date: October 20, 2011Inventors: Ian E. Crandall, Walter A. Szarek, Jason Z. Vlahakis
-
Patent number: 7943650Abstract: Disclosed in certain embodiments is a method of treating and/or mitigating prostate cancer, ovarian cancer, melanoma, colorectal cancer, breast cancer or lung cancer, comprising administering to an individual in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I): where T is optionally substituted phenyl; n is 1 to 6: C represents optionally substituted carbon; and D is imidazolyl; or a pharmaceutically acceptable salt or ester of said compound.Type: GrantFiled: June 16, 2008Date of Patent: May 17, 2011Assignees: Osta Biotechnologies, Queen's University at Kingston, The Sir Mortimer B. Davis-Jewish General HospitalInventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
Publication number: 20110002875Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: June 8, 2010Publication date: January 6, 2011Applicant: Bellus Health (International) LimitedInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Patent number: 7786174Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: GrantFiled: May 22, 2008Date of Patent: August 31, 2010Assignee: Bellus Health (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20100190753Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.Type: ApplicationFiled: August 27, 2009Publication date: July 29, 2010Applicant: BELLUS Health (International) LimitedInventors: Xianqi KONG, Walter A. Szarek, Francine Gervais
-
Patent number: 7754761Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: GrantFiled: February 16, 2007Date of Patent: July 13, 2010Assignee: Bellus Health (International) LimitedInventors: Robert Kisilevsky, Walter A. Szarek, Donald F. Weaver
-
Patent number: 7598269Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.Type: GrantFiled: May 30, 2007Date of Patent: October 6, 2009Assignee: Bellus Health (International) LimitedInventors: Xianqi Kong, Walter A. Szarek, Francine Gervais
-
Publication number: 20090176831Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegencrative disorders and other diseases of the central nervous system.Type: ApplicationFiled: June 16, 2008Publication date: July 9, 2009Applicants: OSTA BIOTECHNOLOGIES, The Sir Mortimer B. Davis - Jewish General Hospital, Queen's University at KingtsonInventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
Publication number: 20090099100Abstract: Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C?O), thiocarbonyl (C?S), sulfonyl (SO2), or sulfoxide (S?O) group. “k” and “m” are 0 or 1, provided when k is 1, R1 is not a hydrogen atom, and when m is 1, R2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. “p” and “s” are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound.Type: ApplicationFiled: July 7, 2008Publication date: April 16, 2009Applicant: Bellus Health (International) LimitedInventors: Walter Szarek, Donald Weaver, Xianqi Kong, Heather Gordon
-
Publication number: 20080227767Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: ApplicationFiled: May 22, 2008Publication date: September 18, 2008Applicant: Neurochem (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Patent number: 7393875Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: GrantFiled: May 2, 2003Date of Patent: July 1, 2008Assignee: Neurochem (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20080015180Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.Type: ApplicationFiled: May 30, 2007Publication date: January 17, 2008Applicant: Neurochem (International) LimitedInventors: Xianqi Kong, Walter Szarek, Francine Gervais
-
Publication number: 20080004244Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: ApplicationFiled: August 2, 2007Publication date: January 3, 2008Applicant: Neurochem (International) LimitedInventors: Walter Szarek, Xianqi Kong, Gregory Thatcher, Boris Gorine
-
Publication number: 20070265334Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: February 16, 2007Publication date: November 15, 2007Applicant: Neurochem (International) LimitedInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver